Drug Profile
BT 301
Alternative Names: BT-301Latest Information Update: 26 Feb 2019
Price :
$50
*
At a glance
- Originator Oscotec
- Developer Oscotec; Yuhan
- Class Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Periodontal disorders
Most Recent Events
- 26 Feb 2019 Discontinued - Phase-II for Periodontal disorders in South Korea (PO)